Although medical technology such as multidrug chemotherapy and surgical removal of the primary tumours has been ameliorated, the survival rate in patients with osteosarcoma remains very low due to its characteristic early metastasis.
Long noncoding RNAs (lncRNAs) are a subgroup of noncoding RNAs (ncRNAs) longer than 200 nucleotides without open reading frames and have no ability to be translated into proteins. 4 Dysregulation of lncRNAs is implicated in a variety of physiological processes such as cell growth and metastasis in osteosarcoma. [5] [6] [7] Small nucleolar RNAs (snoRNAs) as another large class of ncRNAs 8 act a critical role in cancer. For example, lncRNA SNHG1 facilitates tumorigenesis and cancer progression by regulating gene transcription. 9 SNHG5 boosts colorectal cancer growth by inhibiting STAU1-mediated mRNA destabilization 10 and SNHG6 promotes growth and metastasis of hepatocellular carcinoma by competitively binding miR-101-3p. 11 The expression of snoRNA host gene SNHG4 is upregulated in irradiated TK6 cells but is suppressed in bystander cells. 12 However, the function of SNHG4 in cancer is still poorly understood.
In this study, we found that lncRNA SNHG4 was upregulated in osteosarcoma, and SNHG4 expression was associated with tumour size (TS) and poor prognosis in patients with osteosarcoma.
Furthermore, ectopic SNHG4 expression promoted cell proliferation by sponging miR-224-3p. Kaplan-Meier analysis indicated that the osteosarcoma patients with higher expression of SNHG4 or low miR-224-3p possessed a worse prognosis.
| MATERIAL S AND ME THODS

| Clinical data
The clinicopathologic and prognostic data in 136 cases of osteosarcoma patients and 40 adjacent normal tissues as well as the relative expression levels of lncRNA SNHG4 and miRNAs including miR-224-3p were downloaded from The Cancer Genome Atlas (TCGA)
RNA-sequencing database (https://xenabrowser.net/heatmap/). All the osteosarcoma samples were from the biopsies and the pathological stage of osteosarcoma was diagnosed at high grade. The patients with osteosarcoma did not receive any chemotherapy. The clinicopathologic characteristics of 136 osteosarcoma patients were summarized in Table S1 . The protocols used in our study were approved by the Ethics Committee of Renji Hospital, Shanghai Jiao Tong University School of Medicine.
| Identification of miRNAs
The miRNAs that target SNHG4 and the target genes of miR-224-3p
were identified using the microRNA. org forecasting software (http://34.236.212.39/microrna/ getGeneForm.do).
| Cell culture
Osteosarcoma cell lines (MG-63, HOS, 143B, SW-1353, Saos-2, U-2 OS) were cultured in DMEM medium supplemented with 10% heatinactivated FBS, 100 U/mL of penicillin, and 100 μg/mL of streptomycin. Cells in this medium were placed in a humidified atmosphere containing 5% CO 2 at 37°C.
| Quantitative real-time PCR
To quantitatively examine the expression levels of SNHG4 and miR- 
| Western blotting analysis
Saos-2, U-2 OS, MG-63, and HOS cell lines were harvested and their proteins were extracted using lysis buffer. Cell extracts were boiled in loading buffer and equal amount of cell extracts (25 μg) were separated on 15% SDS-PAGE gels. Separated protein bands were transferred into polyvinylidene fluoride membranes. The primary antibodies against DOCK7 (ab71858, mouse polyclonal antibody; Abcam, Cambridge, MA, USA) and PCNA (ab29, mouse monoclonal antibody; Abcam) were diluted at a ratio of 1:1000 and the second antibodies were diluted at a ratio of 1:10 000 according to the instructions. Western blotting analysis was performed as previously reported. 
| Luciferase reporter assay
Saos-2 and U-2 OS cell lines were seeded into 24-well plates.
After 24 hours incubation, 6 ng of pmirGLO report vector carrying wild-type 3′-UTR or mutated 3′-UTR of SNHG4 or DOCK7
gene was cotransfected with miR-224-3p (100 nmol/L) or miR-NC (100 nmol/L) into the Saos-2 and U-2 OS cells. Forty-eight hours after transfection, luciferase activities were examined with a Dualluciferase Reporter System (Promega, Madison, WI, USA).
| Plasmid and miR-224-3p mimic
Plasmid-mediated pcDNA3.1 and pcDNA3.1-DOCK7 vectors, miR-224-3p mimic, and miR-NC were purchased from Genepharma 
| Cell viability and colony formation assays
Cell viability and colony formation assays were conducted as previously reported. 13 Cell proliferation was analysed using the MTT 
| Statistical analysis
We carried out the statistical analyses using SPSS 20.0 (IBM; SPSS, Chicago, IL, USA) and GraphPad Prism. Student's t test or chi-square test was utilized to analysed the statistical significance for the comparisons of two groups. Pearson's correlation coefficient analysis was used to analyse the correlations of SNHG4 with miRNAs.
Survival and recurrence curves were plotted using the Kaplan-Meier method and assessed for the statistical significance using a log-rank test. Statistical significance was set at P < 0.05.
| RE SULTS
| The expression of lncRNA SNHG4 is upregulated in human osteosarcoma
The expression level of lncRNA SNHG4 in human osteosarcoma samples was evaluated using TCGA RNA-seq data, which indicated that the expression level of SNHG4 was markedly increased in osteosarcoma samples as compared with adjacent normal tissues as well as in pair-matched osteosarcoma ( Figure 1A ). To probe the association between SNHG4 expression and TS in osteosarcoma, we assessed the expression level of SNHG4 in patients with tumour size (TS) ≥5 cm and those with TS <5 cm, indicating that SNHG4 expression was upregulated in patients with TS ≥5 cm as compared with those with TS <5 cm ( Figure 1B ).
| LncRNA SNHG4 exhibits a positive correlation with tumour size and poor prognosis in patients with osteosarcoma
To verify the association between SNHG4 expression and the clinical significance in patients with osteosarcoma, we analysed the association between SNHG4 expression and clinicopathologic characteristics and prognosis in patients with osteosarcoma. As shown in Figure 1C , the cut-off value of SNHG4 was obtained based on its expression level, survival time, and survival status in patients with osteosarcoma, and according to this cut-off value, the 136 patients were divided into two groups: SNHG4 high expression and SNHG4 low expression ( Figure S1 ). Receiver operating characteristic curve and area under curve (AUC) were used to evaluate the sensitivity and specificity of SNHG4. The sensitivity, specificity, and AUC of SNHG4 were 52.7%, 69.1%, and 0.54, indicating that SNHG4 might be the potential biomarker for the survival of patients with osteosarcoma.
As shown in Table S3 , SNHG4 high expression was positively associated with tumour size (P = 0.020), but displayed no correlation with other clinical parameters (P > 0.05). Kaplan-Meier analysis demonstrated that the osteosarcoma patients with SNHG4 high expression developed lower survival rate ( Figure 1D ) and higher tumour recurrence ( Figure 1E ), as compared with the patients with SNHG4 low expression. To determine whether SNHG4 expression was an independent prognostic factor in patients with osteosarcoma, we conducted the multivariate analyses using a Cox proportional hazard model. As shown in Tables S4,S5 , in the univariate analysis, distant metastasis was associated with overall survival and recurrence, but in the final multivariate Cox regression model, distant metastasis rather than SNHG4 indicated an independent prognostic factor of survival and recurrence in patients with osteosarcoma.
| Knockdown of SNHG4 inhibits cell proliferation and colony formation
Having confirmed the positive correlation of SNHG4 expression with tumour size in patients with osteosarcoma ( Figure 1B and Table S3) 
| Ectopic SNHG4 expression promotes cell proliferation and colony formation
Having demonstrated the antigrowth effects of si-SNHG4 in os- Figure 3D ). 
| miR-224-3p mimic reverses SNHG4-induced tumour-promoting effects
Having validated the tumour-promoting effects of SNHG4 and its negative correlation with miR-224-2p expression, we further assessed their functional relationship in osteosarcoma cells. After
Saos-2 and U-2 OS cells were cotransfected with miR-224-3p mimic and SNHG4 overexpression vector, we evaluated cell viability and colony formation abilities by MTT ( Figure 5A ) and colony formation assays ( Figure 5B ), indicating that miR-224-3p mimic repressed cell viability and colony formation, and counteracted SNHG4-induced tumour promoting effects in osteosarcoma cells ( Figure 5A,B) .
In addition, it has been reported that miR-224-3p functions by regulating its target genes. 14, 15 According to the mirSVR scoring, dedicator of cytokinesis 7 (DOCK7) was identified to be the most likely target gene of miR-224-3p (Table S6) Figure 5E ). Western blot analysis showed that miR-224-3p mimic downregulated the expression of DOCK7, but this effect was reversed by DOCK7 overexpression in Saos-2 and U-2 OS cells ( Figure 5F ). Furthermore, we found that, according to the cut-off value ( Figure S4A ), the patients with osteosarcoma were divided into DOCK7 high-expression and low-expression groups ( Figure S4B ), and the patients with DOCK7
high expression harboured the poorer survival ( Figure S4C ) and higher tumour recurrence ( Figure S4D ) as compared with those with DOCK7 low expression aberrantly expressed in osteosarcoma and is it associated with OS progression?
| Low expression of miR-224-3p is associated with tumour size and poor survival in patients with osteosarcoma
The expression level of miR-224-3p in osteosarcoma samples was assessed using TCGA RNA-seq data, indicating that the expression level of miR-224-3p was substantially decreased in osteosarcoma samples as compared with the adjacent normal tissues as well as in pair-matched osteosarcoma ( Figure 6A ). We also found that miR-224-3p expression was downregulated in patients with TS ≥5 cm as compared with those with TS <5 cm ( Figure 6B) . Then, the association between miR-224-3p expression and clinicopathologic characteristics and prognosis in patients with osteosarcoma was analysed.
As indicated in Fig. 6C , according to the cut-off value of miR-224-3p, the patients were divided into miR-224-3p high-expression group and low-expression group ( Figure S5 ). As shown in Table S7 , miR-224-3p low expression was correlated with tumour size (P = 0.038),
but exhibited no correlation with other clinical factors (P > 0.05).
Kaplan-Meier analysis indicated that the osteosarcoma patients with miR-224-3p low expression had shorter survival time ( Figure 6D ), but had no difference in tumour recurrence ( Figure 6E ), as compared with the patients with miR-224-3p high expression. As shown in Table S8 , in the univariate and multivariate Cox regression analysis, distant metastasis rather than miR-224-3p expression was an independent prognostic factor of survival in patients with osteosarcoma.
| D ISCUSS I ON
Increasing data demonstrate that lncRNA SNHGs are correlated with osteosarcoma tumorigenesis and progression. For example, SNHG1 facilitates osteosarcoma tumorigenesis by sponging miR-326, 16 and promotes its metastasis by activating Wnt/β-catenin signalling. 17 SNHG12 promotes growth and metastasis of osteosarcoma 18 and inhibition of SNHG12-miR-195 axis suppresses tumour growth. 19 However, the role of SNHG4 in osteosarcoma remains unclear. In this study, we found that the expression level of In regard to the functions of lncRNA SNHG4, there is little knowledge about its roles in cancer. Herein, our study showed that SNHG4 promoted osteosarcoma cell proliferation and colony formation, but knockdown of SNHG4 had the opposite effects. In addition, PCNA as cell proliferation-related marker mediates key signalling pathways to regulate osteosarcoma cell growth. 20, 21 We assessed the effects of SNHG4 on PCNA expression by western blot analysis, and found that SNHG4 increased PCNA expression, while knockdown of SNHG4 decreased its expression, suggesting that SNHG4 might promote the growth of osteosarcoma cells by upregulating PCNA expression.
Mechanically, accumulating evidence reveals that lncRNA functions as competing endogenous RNAs (ceRNAs) to regulate cell growth by sponging miRNAs. 11, [16] [17] [18] Some studies demonstrate that lncRNA SNHG1 promotes the tumorigenesis by sponging miR-577, 17 and SNHG12 acts by sponging miR-195-5p 18 in osteosarcoma. In the present study, we identified the miR-224-3p specific binding with SNHG4 and revealed the negative correlation between SNHG4 and miR-224-3p expression in osteosarcoma samples. SNHG4 was further validated as a sponge of miR-224-3p in osteosarcoma cells, indicating that SNHG4 promoted osteosarcoma growth by sponging miR-224-3p.
It is reported that miR-224 acts a dual role in cancer. On the one hand, increased expression of miR-224-5p harbours the potential to be a diagnostic and prognostic biomarker in digestive system cancers, 22 and is associated with the cisplatin resistance in ovarian carcinoma. 23 On the other hand, miR-224-3p represses autophagy in cervical cancer by targeting FIP200 14 and is downregulated in multidrug-resistant breast cancer cells. 15 In our study, miR-224-3p was found downregulated in osteosarcoma and was correlated with tumour size and poor survival. Overexpression of miR-224-3p suppressed cell proliferation and counteracted the SNHG4-induced tumour-promoting effects. Furthermore, we identified DOCK7 as an important target of miR-224-3p in osteosarcoma cells. DOCK7 has been reported elevated in human glioblastoma multiforme, and mediates HGF-induced glioblastoma cell invasion. 24 DOCK7 is a key regulator of the RAGE-Cdc42 signalling and induces dendritic pseudopodia in cancer cells. 25 We also found that DOCK7 high expression was associated with poor survival and tumour recurrence in patients with osteosarcoma, and ectopic expression of DOCK7 promoted cell proliferation and reversed the antiproliferation effects of miR-224-3p in osteosarcoma cells. These results suggested that lncRNA SNHG4 contributed to osteosarcoma growth by sponging miR-224-3p and upregulating DOCK7 expression.
| CON CLUS IONS
In conclusions, our findings demonstrated that lncRNA SNHG4 facilitated the growth of osteosarcoma cells by sponging miR-224-3p and regulating DOCK7 expression, and provided the potential marker for the patients with osteosarcoma. 
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